Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1994 1
1995 2
1996 1
1997 2
1998 1
2001 3
2003 3
2004 1
2005 1
2006 3
2007 2
2008 7
2009 4
2010 4
2011 5
2012 7
2013 12
2014 11
2015 10
2016 11
2017 17
2018 14
2019 16
2020 8
Text availability
Article attribute
Article type
Publication date

Search Results

131 results
Results by year
Filters applied: . Clear all
Page 1
Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, Post FA, Wearne N, Winkler CA, Cheung M, Wheeler DC, Winkelmayer WC, Wyatt CM; Conference Participants. Swanepoel CR, et al. Among authors: Post FA. Kidney Int. 2018 Mar;93(3):545-559. doi: 10.1016/j.kint.2017.11.007. Epub 2018 Feb 3. Kidney Int. 2018. PMID: 29398134 Free PMC article.
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M. Gupta SK, et al. Among authors: Post FA. AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223. AIDS. 2019. PMID: 30932951 Free PMC article.
Kidney disease in Africans with HIV and tuberculosis.
Wearne N, Hung R, Bohmer R, Spies R, Omar A, Ash S, Ibrahim F, Miller RF, Booth JW, Lucas SB, Post FA. Wearne N, et al. Among authors: Post FA. AIDS. 2019 Jun 1;33(7):1207-1213. doi: 10.1097/QAD.0000000000002204. AIDS. 2019. PMID: 30932966
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, Post FA, Morales-Ramirez J, Thompson M, Osiyemi O, Rashbaum B, Stellbrink HJ, Martorell C, Liu H, Liu YP, Porter D, Collins SE, SenGupta D, Das M. Hagins D, et al. Among authors: Post FA. HIV Med. 2018 Nov;19(10):724-733. doi: 10.1111/hiv.12664. Epub 2018 Aug 12. HIV Med. 2018. PMID: 30101539 Free PMC article. Clinical Trial.
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Winston A, Post FA, DeJesus E, Podzamczer D, Di Perri G, Estrada V, Raffi F, Ruane P, Peyrani P, Crofoot G, Mallon PWG, Castelli F, Yan M, Cox S, Das M, Cheng A, Rhee MS. Winston A, et al. Among authors: Post FA. Lancet HIV. 2018 Apr;5(4):e162-e171. doi: 10.1016/S2352-3018(18)30010-9. Epub 2018 Feb 20. Lancet HIV. 2018. PMID: 29475804 Free article. Clinical Trial.
Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study.
Whitworth HS, Badhan A, Boakye AA, Takwoingi Y, Rees-Roberts M, Partlett C, Lambie H, Innes J, Cooke G, Lipman M, Conlon C, Macallan D, Chua F, Post FA, Wiselka M, Woltmann G, Deeks JJ, Kon OM, Lalvani A; Interferon-γ Release Assays for Diagnostic Evaluation of Active Tuberculosis study group. Whitworth HS, et al. Among authors: Post FA. Lancet Infect Dis. 2019 Feb;19(2):193-202. doi: 10.1016/S1473-3099(18)30613-3. Epub 2019 Jan 14. Lancet Infect Dis. 2019. PMID: 30655049 Free article. Clinical Trial.
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>
Post FA, Yazdanpanah Y, Schembri G, Lazzarin A, Reynes J, Maggiolo F, Yan M, Abram ME, Tran-Muchowski C, Cheng A, Rhee MS. Post FA, et al. HIV Clin Trials. 2017 May;18(3):135-140. doi: 10.1080/15284336.2017.1291867. Epub 2017 Mar 17. HIV Clin Trials. 2017. PMID: 28303753 Clinical Trial.
Optimizing antiretroviral regimens in chronic kidney disease.
Hamzah L, Jones R, Post FA. Hamzah L, et al. Among authors: Post FA. Curr Opin Infect Dis. 2019 Feb;32(1):1-7. doi: 10.1097/QCO.0000000000000509. Curr Opin Infect Dis. 2019. PMID: 30461453 Review.
Promoting high standards of care for women living with HIV: position statement from the Women Against Viruses in Europe Working Group.
Kowalska JD, Aebi-Popp K, Loutfy M, Post FA, Perez-Elias MJ, Johnson M, Mulcahy F; Women Against Viruses in Europe (WAVE) Working Group. Kowalska JD, et al. Among authors: Post FA. HIV Med. 2018 Feb;19(2):167-173. doi: 10.1111/hiv.12565. Epub 2017 Nov 21. HIV Med. 2018. PMID: 29159861 Free article. Review.
Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study.
Bagkeris E, Burgess L, Mallon PW, Post FA, Boffito M, Sachikonye M, Anderson J, Asboe D, Garvey L, Vera J, Williams I, Johnson M, Babalis D, De Francesco D, Winston A, Sabin CA. Bagkeris E, et al. Among authors: Post FA. Int J Epidemiol. 2018 Oct 1;47(5):1391-1392e. doi: 10.1093/ije/dyy072. Int J Epidemiol. 2018. PMID: 29746638 Free article. Clinical Trial. No abstract available.
131 results
Jump to page